| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.45▲ | 1.44▲ | 1.43▲ | 1.30▲ | 1.29▲ |
| MA10 | 1.45▲ | 1.42▲ | 1.39▲ | 1.32▲ | 1.36▲ |
| MA20 | 1.43▲ | 1.37▲ | 1.31▲ | 1.29▲ | 1.46▲ |
| MA50 | 1.38▲ | 1.30▲ | 1.35▲ | 1.36▲ | 0.99▲ |
| MA100 | 1.31▲ | 1.32▲ | 1.27▲ | 1.43▲ | 3.45▼ |
| MA200 | 1.33▲ | 1.31▲ | 1.35▲ | 0.99▲ | 6.48▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.001▼ | 0.008▲ | 0.020▲ | 0.020▲ | -0.028▼ |
| RSI | 68.280▲ | 70.248▲ | 71.030▲ | 56.846▲ | 54.115▲ |
| STOCH | 49.167 | 84.618▲ | 84.929▲ | 52.543 | 40.370 |
| WILL %R | -14.286▲ | -5.556▲ | -3.448▲ | -18.367▲ | -50.588 |
| CCI | 183.221▲ | 120.554▲ | 120.956▲ | 97.563 | -26.798 |
|
Thursday, January 15, 2026 02:39 PM
ALX Oncology (NASDAQ:ALXO) outlined progress across its two clinical-stage programs—CD47 blocker evorpacept and EGFR-targeted antibody-drug conjugate (ADC) ALX2004—during a presentation at the J.P.
|
|
Thursday, January 08, 2026 08:17 AM
The live webcast of the J.P. Morgan fireside chat can be accessed by visiting the Investors section of ALX Oncology’s website at www.alxoncology.com under the Events section of the Events and ...
|
|
Thursday, January 08, 2026 05:50 AM
First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician’s choice of ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 21/01/26 | 1.34 | 1.48 | 1.32 | 1.47 | 247,275 |
| 20/01/26 | 1.16 | 1.36 | 1.16 | 1.32 | 280,251 |
| 16/01/26 | 1.22 | 1.27 | 1.16 | 1.17 | 204,477 |
| 15/01/26 | 1.33 | 1.40 | 1.205 | 1.21 | 241,598 |
| 14/01/26 | 1.50 | 1.50 | 1.315 | 1.33 | 282,441 |
| 13/01/26 | 1.46 | 1.56 | 1.44 | 1.49 | 198,415 |
| 12/01/26 | 1.41 | 1.49 | 1.37 | 1.44 | 243,406 |
| 09/01/26 | 1.27 | 1.40 | 1.245 | 1.35 | 277,485 |
| 08/01/26 | 1.18 | 1.34 | 1.18 | 1.24 | 312,607 |
| 07/01/26 | 1.09 | 1.22 | 1.08 | 1.18 | 164,737 |
|
|
||||
|
|
||||
|
|